Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Organon ( (OGN) ) has shared an announcement.
On June 10, 2025, Organon held its Annual Meeting where stockholders voted on five proposals. The meeting saw approximately 83% of shares represented, with key decisions including the election of eleven directors, approval of executive compensation, amendment of the 2021 Incentive Stock Plan, ratification of PricewaterhouseCoopers LLP as the accounting firm, and rejection of a stockholder proposal for a new Director Election Resignation Guideline.
The most recent analyst rating on (OGN) stock is a Sell with a $20.00 price target. To see the full list of analyst forecasts on Organon stock, see the OGN Stock Forecast page.
Spark’s Take on OGN Stock
According to Spark, TipRanks’ AI Analyst, OGN is a Neutral.
Organon faces significant challenges with declining revenues and high leverage, reflected in the financial performance score. Technical indicators are bearish, and although the valuation appears attractive, it suggests underlying risks. Positives from the earnings call and FDA approval of HADLIMA offer some optimism, but financial stability concerns weigh heavily on the overall score.
To see Spark’s full report on OGN stock, click here.
More about Organon
Average Trading Volume: 5,873,353
Technical Sentiment Signal: Sell
Current Market Cap: $2.61B
See more data about OGN stock on TipRanks’ Stock Analysis page.